Claims for Patent: 7,560,436

Summary for Patent: 7,560,436

Title:	Methods of treating gastrointestinal inflammation
Abstract:	The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn\'s Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.
Inventor(s):	Raz; Eyal (Del Mar, CA), Katakura; Kyoko (San Diego, CA), Lee; Jongdae (San Diego, CA), Rachmilewitz; Daniel (Tel Aviv, IL)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	11/359,945
Patent Claims:	1. A method for treating a gastrointestinal inflammatory disorder in an individual, the method comprising administering to a subject suffering from a gastrointestinal inflammatory disorder an effective amount of Type I interferon activating agent that increases the level of a Type I interferon and/or activates a Type I interferon signaling pathway, wherein said Type I interferon activating agent is a chimeric toll-like receptor (TLR) ligand comprising a TLR9 agonist moiety and a TLR8 agonist moiety, a chimeric TLR ligand comprising a TLR9 agonist moiety and a TLR7 agonist moiety, or a chimeric TLR ligand comprising a TLR7 agonist moiety and a TLR8 agonist moiety. 2. The method of claim 1, wherein the TLR7 agonist moiety selected from an imidazoquinoline compound, a C8-substituted guanine ribonucleotides, and an N7, C8-substituted guanine ribonucleotide. 3. The method of claim 2, wherein the TLR7 agonist moiety is a selective TLR7 agonist. 4. The method of claim 1, wherein the TLR8 agonist moiety is an amide substituted imidazoquinoline amine. 5. The method of claim 4, wherein the TLR8 agonist moiety is a selective TLR8 agonist. 6. The method of claim 1, further comprising administering at least one additional therapeutic agent that treats a gastrointestinal inflammatory disorder. 7. The method of claim 6, wherein the at least one additional therapeutic agent is selected from an immunosuppressant, an anti-malarial agent, a TNF-.alpha. antagonist, an aminosalicylate, a corticosteroid, and a non-steroidal anti-inflammatory drug. 8. The method of claim 7, wherein the at least one additional therapeutic agent is an immunosuppressant selected from azothioprine, tacrolimus, cyclophosphamide, and cyclosporine. 9. The method of claim 7, wherein the at least one additional therapeutic agent is hydroxychloroquine. 10. The method of claim 7, wherein the at least one additional therapeutic agent is a TNF-.alpha. antagonist selected from etanercept, infliximab, and adalimumab. 11. The method of claim 7, wherein the at least one additional therapeutic agent is selected from 5-aminosalicylate, sulfasalazine, olsalazine and mesalamine. 12. The method of claim 7, wherein the at least one additional therapeutic agent is a corticosteroid selected from prednisolone, dexamethasone, hydrocortisone, and prednisone. 13. The method of claim 1, wherein said administering is by an oral route. 14. The method of claim 1, wherein said administering is by a subcutaneous route. 15. The method of claim 1, wherein said administering is by a rectal route. 16. The method of claim 1, wherein the gastrointestinal inflammatory disorder is chronic gastrointestinal inflammation. 17. The method of claim 1, wherein the chronic gastrointestinal inflammation is caused by inflammatory bowel disease. 18. The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis. 19. The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease. 20. The method of claim 1, wherein the gastrointestinal inflammatory disorder is acute gastrointestinal inflammation. 21. The method of claim 1, wherein the gastrointestinal inflammatory disorder is pouchitis. 22. The method of claim 1, further comprising administering an effective amount of an IFN-.alpha.. 23. The method of claim 1, further comprising administering an effective amount of an IFN-.beta.. 24. The method of claim 1, wherein the individual is a human.

Details for Patent 7,560,436

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2025-02-22
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2025-02-22
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2025-02-22
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2025-02-22
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2025-02-22
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2025-02-22